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Abstract. 
 
Mitogen-activated protein kinases (p42/p44 
MAPK, also called Erk2 and Erk1) are key mediators 
of signal transduction from the cell surface to the nu-
cleus. We have previously shown that the activation of 
p42/p44 MAPK required for transduction of mitogenic 
signaling is associated with a rapid nuclear transloca-
tion of these kinases. However, the means by which p42 
and p44 MAPK translocate into the nucleus after cyto-
plasmic activation is still not understood and cannot 
simply be deduced from their protein sequences. In this 
study, we have demonstrated that activation of the p42/
p44 MAPK pathway was necessary and sufficient for 
triggering nuclear translocation of p42 and p44 MAPK. 
First, addition of the MEK inhibitor PD 98059, which 
blocks activation of the p42/p44 MAPK pathway, im-
pedes the nuclear accumulation, whereas direct activa-
tion of the p42/p44 MAPK pathway by the chimera 
 
D
 
Raf-1:ER is sufficient to promote nuclear accumula-
tion of p42/p44 MAPK. In addition, we have shown 
that this nuclear accumulation of p42/p44 MAPK re-
quired the neosynthesis of short-lived proteins. Indeed, 
inhibitors of protein synthesis abrogate nuclear accu-
mulation in response to serum and accelerate p42/p44 
MAPK nuclear efflux under conditions of persistent 
p42/p44 MAPK activation. In contrast, inhibition of 
targeted proteolysis by the proteasome synergistically 
potentiated p42/p44 MAPK nuclear localization by 
nonmitogenic agonists and markedly prolonged nuclear 
localization of p42/p44 MAPK after mitogenic stimula-
tion. We therefore conclude that the MAPK nuclear 
translocation requires both activation of the p42/p44 
MAPK module and neosynthesis of short-lived pro-
teins that we postulate to be nuclear anchors.
Key words: growth factors • signal transduction • pro-
tein kinases • cell compartmentation • cell nucleus
 
T
 
he
 
 sequence of events linking cell surface receptor–
mediated signals to expression of specific genes has
received considerable attention over the years. One
of such signaling modules is the p42/p44 mitogen-activated
protein kinase (MAPK)
 
1
 
 pathway, which transmits signal-
ing from receptor tyrosine kinases, some G protein–cou-
pled receptors, cytokine receptors, and integrins through
the following activation cascade: Ras/Raf/MAPK kinase
(MEK)/p42/p44 MAPK (for reviews see 25, 41). Among
all the members of this signaling cascade, p44 and p42
MAPK isoforms (equivalent to Erk1 and Erk2) have been
shown to be the only ones able to accumulate in the nu-
cleus after mitogenic stimulation (8, 18, 27). In relation to
this nuclear event, it has been demonstrated that p42/p44
MAPK phosphorylate multiple transcription factors, Elk-1
being one of the best characterized examples (16, 29), for
which phosphorylation by p42/p44 MAPK has been dem-
onstrated to increase its transcriptional activity (17, 21).
Recently, Jaaro et al. (23) have shown that truncated or
mutated forms of MEK can localize in the nucleus, but
they confirm our initial report that the wild-type form of
MEK remains in the cytoplasm (27), a feature dependent
on a nuclear export signal in its sequence (14, 23). Thus, al-
though MEK may enter in the nucleus, it is readily ex-
ported and thus cannot be found accumulated in it (14, 27,
35, 48). The mechanism by which p42/p44 MAPK are se-
questered in the cytoplasm in resting cells and translocate
to the nucleus upon mitogenic stimulation is still unknown.
Certainly, it cannot be explained by the unmasking of a ca-
nonical nuclear localization signal (NLS) (6) that would
accelerate this transfer to the nucleus (for reviews on nu-
cleocytoplasmic transfer see 38, 40). Nuclear localization
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of p42/p44 MAPK is reversible (8, 18, 27), and the only
known reversible modification of p42 and p44 MAPK is
their dual phosphorylation upon activation by MEK (1, 10,
47). We and others have demonstrated that nonphosphor-
ylatable and inactive mutated forms of p44 MAPK are still
able to translocate to the nucleus (18, 26, 27). Recently,
Khokhlatchev et al. (26) reported that microinjected mu-
tants of p42 MAPK can dimerize with phosphorylated
wild-type p42 MAPK to enter the nucleus. Further studies
are needed to clarify the role of MAPK dimerization in
the mechanism of nuclear translocation.
In this study, however, we have demonstrated in vivo
that activation of the p42/p44 MAPK plays a key role in
triggering its nuclear translocation. Moreover, this activa-
tion is both necessary and sufficient. Indeed, blocking the
activation of p42/p44 MAPK with the MEK inhibitor Park
Davis 98059 (PD 98059; references 2, 12) impedes nuclear
accumulation of p42/p44 MAPK, while the sole activation
of this pathway by the chimera 
 
D
 
Raf-1:ER (28, 43, 44) re-
sults in the nuclear accumulation of p42/p44 MAPK. In ad-
dition, we have shown that the nuclear accumulation of
p42/p44 MAPK that peaks after 3 h of serum stimulation
requires the neosynthesis of short-lived proteins. Blocking
serum-dependent transcriptional activation by actinomy-
cin D or blocking protein synthesis by cycloheximide, two
actions that do not suppress MAPK activation by serum,
impedes nuclear accumulation of p42/p44 MAPK. In addi-
tion, blocking protein synthesis during mitogenic stimula-
tion accelerates the efflux of p42/p44 MAPK from the nu-
cleus. This result indicates that the proteins that contribute
to the nuclear retention of p42/p44 MAPK are short-lived.
In fact, the stabilization of these short-lived proteins via
inhibition of targeted proteolysis by the proteasome (for
reviews see 4, 42) greatly potentiated p42/p44 MAPK nu-
clear localization. However, the rapid entry of MAPK into
the nucleus does not require protein synthesis. In conclu-
sion, the data presented here lead us to dissociate two
events: the rapid nuclear entry of p42/p44 MAPK and the
nuclear accumulation of p42/p44 MAPK. Both processes
require robust activation of p42/p44 MAPK, the second
being dependent on neosynthesis of short-lived proteins
(most likely nuclear anchors) induced by activation of the
p42/p44 MAPK cascade.
 
Materials and Methods
 
Materials
 
Texas red–conjugated anti–rabbit antibody was purchased from Molecu-
lar Probes (Eugene, OR) and CITIFLUOR was purchased from UKC
Chem Lab (Canterbury, UK). Anti-MAPK antibody R2 was obtained
from Upstate Biotechnologies, Inc. (Lake Placid, NY). This antibody was
directed against the peptide sequence corresponding to the amino acids
333–367 of the COOH terminus of Rat Erk1 (catalog #06-182). The pro-
teasome inhibitor 
 
N
 
-Acetyl-Leu-Leu-norLeucinal (LLnL) was purchased
from Sigma Chemical Co. (St. Louis, MO). The proteasome inhibitor lac-
tacystin (synthetic) was purchased from Calbiochem (La Jolla, CA). All
other chemicals were of the highest purity available.
 
Cell Line and Cell Culture
 
Chinese hamster lung fibroblasts CCL39 were maintained in DME (cata-
log #52100; Life Technologies, Inc., Gaithersburg, MD) containing 25 mM
NaHCO
 
3
 
. The derived CCL39-
 
D
 
Raf-1:ER clone (28) was maintained in
DME without phenol red and supplemented with glutamine and glucose
to reach the concentrations of normal DME (catalog #11880). Both cul-
ture media were supplemented with 7.5% FCS (GIBCO-BRL; Life Tech-
nologies, Inc.), penicillin (50 U/ml), and streptomycin (50 
 
m
 
g/ml). Cells
were maintained at 37
 
8
 
C in the presence of 5% CO
 
2
 
.
The CCL39-
 
D
 
Raf-1:ER clonal cell line was obtained by transfection of
CCL39 cells with the plasmid pLNC
 
D
 
Raf-1:ER (44) and selection of
clones resistant to Geneticin (G418, GIBCO-BRL). The clone that dis-
played the highest stimulation of p42/p44 MAPK activity upon 
 
b
 
-estradiol
addition was selected, and its characteristics were reported (28).
Quiescent cells (G0-arrested) were obtained by incubating confluent
cultures in serum-free medium for 24–48 h. Cells were then treated with
various agents as described in Results and figure legends.
 
Indirect Immunofluorescence Analysis
 
G0-arrested or serum-stimulated CCL39 cells were fixed at 
 
2
 
20
 
8
 
C for 10
min with methanol/acetone (70:30, vol/vol) without previous PBS wash.
After a 10-min rehydration at 25
 
8
 
C in PBS containing 10% FCS (PBS/
FCS), fixed cells were then incubated with the R2 antibody from Upstate
Biotechnologies, Inc., for 60 min at 25
 
8
 
C in PBS/FCS (dilution 1:2,000).
Cells were then washed five times with PBS and incubated in PBS/FCS for
60 min at 25
 
8
 
C with Texas red–conjugated anti–rabbit antibody (1:500).
Finally, cells were washed five times with PBS, mounted under glass cov-
erslides with CITIFLUOR media, and examined under epifluorescent il-
lumination with excitation-emission filters for Texas red. To control for
specificity, (
 
a
 
) the same results were obtained when cells were fixed with
1% paraformaldehyde in methanol at 
 
2
 
20
 
8
 
C for 15 min or with 4%
paraformaldehyde in PBS at 20
 
8
 
C for 15 min followed by permeabilization
with 0.2% Triton X-100 in PBS for 5 min at 20
 
8
 
C (data not shown), and
(
 
b
 
) incubation with secondary antibody alone did not reveal any signifi-
cant fluorescent signal (data not shown). R2 antibodies raised against the
last 35 amino acids of Rat Erk1 are in fact very specific for p44 MAPK.
This was resolved by using mouse embryo fibroblasts lacking Erk1 that we
have obtained in our laboratory. With these cells, we showed that p42
MAPK translocation and retention in the nucleus follow the same fea-
tures as those of p44 MAPK. Therefore, we invariably denote transloca-
tion of p42/p44 MAPK all along this manuscript.
 
SDS-PAGE and Immunoblotting
 
Confluent cells were lysed in a lysis buffer (0.1% Triton X-100, 50 mM
Tris-HCl, pH 7.5, 5 mM EDTA, 1 mM phenylmethanesulfonyl fluoride,
1 mM benzamidine, 40 mM paranitrophenylphosphate, and 200 
 
m
 
M
orthovanadate). 25 
 
m
 
g of detergent-extracted proteins were separated by
SDS-PAGE on a 12.5% (wt/vol) polyacrylamide gel (30:0.2) and electro-
phoretically transferred to immobilon-P membrane (Millipore Corp.,
Bedford, MA). Immunoprobing was performed with the antibody E1B as
previously described (28).
 
p42/p44 MAPK Kinase Assay
 
p42/p44 MAPK activity was assayed as previously described (28). In brief,
cells were lysed in the lysis buffer described in the previous section. After
centrifugation to remove insoluble cell fragments, the supernatant was in-
cubated with 5 
 
m
 
l of the MAPK precipitating antibody Kelly as previously
described (28) and protein A–Sepharose (Pharmacia Biotech, Piscataway,
NJ). The immune complex was washed five times with the lysis buffer and
once with the kinase buffer without substrate. Immunoprecipitated
MAPK was then incubated for 20 min at 30
 
8
 
C in the kinase buffer: 20 mM
Hepes, pH 7.4, 10 mM MgCl
 
2
 
, 1 mM dithiothreitol, 20 mM paranitrophe-
nylphosphate, 0.25 mg/ml myelin basic protein and 30 
 
m
 
M ATP (3 
 
m
 
Ci of
[
 
g
 
32
 
P]ATP). The kinase reaction was stopped by adding Laemmli buffer,
and the myelin basic protein was separated by an SDS–polyacrylamide gel
(10%, 29:1). Radioactivity was measured by the MACBASS quantifica-
tion program of the Fuji Phosphoimager (Tokyo, Japan).
 
Results
 
Activation of the p42/p44 MAPK Pathway Is Necessary 
for Inducing Nuclear Translocation of p42/p44 MAPK
 
We previously reported that mitogenic stimulation of rest-
ing CCL39 cells led to a rapid nuclear translocation of
MAPKs into the nucleus (27). Translocation into the nu- 
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cleus correlated nicely with the persistent activation of
MAPK during the G1 phase of the cell cycle. For example,
serum or 
 
a
 
-thrombin, two potent mitogens of CCL39 cells,
induced persistent MAPK activation and nuclear localiza-
tion. In contrast, the thrombin receptor peptide activator
or TPA, which transiently activates MAPK, failed to in-
duce nuclear translocation of MAPK (27). This result led
us to postulate that the p42/p44 MAPK cascade itself con-
trols the nuclear translocation of MAPK. Therefore, we
tested whether addition of the specific MEK inhibitor PD
98059 (12) was sufficient to block the entry of p42/p44
MAPK in the nucleus in response to serum. This inhibitor
has been previously shown to inhibit by up to 90% MAPK
activation without affecting the activation of other MAPK
cascades, such as the JNK and p38 MAPK pathways (2).
In accordance to our and others’ previous observations,
p42/p44 MAPK immunostaining is predominantly cytoplas-
mic in serum-deprived cells (Fig. 1 
 
A
 
) and in cells treated by
the MEK inhibitor PD 98059 alone (Fig. 1 
 
D
 
), whereas
within 3 h of stimulation by 10% FCS, it is relocated mark-
edly in the nucleus (Fig. 1 
 
B
 
). As depicted in Fig. 1 
 
C
 
, the
addition of the MEK inhibitor PD 98059 (30 
 
m
 
M) at the
time of serum addition was sufficient to block nuclear trans-
location of p42/p44 MAPK. As was reported by Alessi et al.
(2) we found that MAPK activity was not totally inhibited
by 30 
 
m
 
M of PD 98059 compound in CCL39 cells (up to
80% inhibition). This incomplete inhibition could explain
why in certain cells some nuclear localization of p42/p44
MAPK remained. In these cells it is possible that MAPK
stimulation by serum may be extremely potent. However,
this result indicates that activation of the p42/p44 MAPK
signaling cascade in response to serum is absolutely re-
quired for nuclear translocation of p42/p44 MAPK.
 
Persistent Activation of p42/p44 MAPK in Cells 
Expressing the 
 
D
 
Raf-1:ER Chimera
 
To evaluate whether the sole activation of the p42/p44
MAPK signaling module is sufficient to promote nuclear
translocation of p42/p44 MAPK, we have taken advantage
of a fibroblastic cell line CCL39-
 
D
 
Raf-1:ER (28) stably ex-
pressing the chimera 
 
D
 
Raf-1:ER (43, 44). Upon addition
of 
 
b
 
-estradiol to these cells, the Raf-1 kinase moiety of the
chimera is unmasked and rapidly phosphorylates MEK,
which in turn activates p42/p44 MAPK (28). As shown in
Fig. 2 
 
A
 
, serum stimulation retards the electrophoretic
mobility of p42 MAPK (due to phosphorylation). This ac-
tivation observed after 15 min persists for up to 6 h, de-
clines after 9 h, and is not detectable at 12 h when cells en-
ter S-phase (Fig. 2 
 
A
 
). In sharp contrast, activation of the
same cells with estradiol induces a gel mobility shift that
persists as long as the cells are treated with estradiol (Fig.
2 
 
B
 
). In this experiment, only p42 MAPK is detected be-
cause of the specificity of the antibody used. However, ac-
tivation of p44 MAPK (revealed with a less selective anti-
MAPK antibody) parallels activation of p42 MAPK. The
CCL39-
 
D
 
Raf-1:ER cell line offers two unique advantages.
First, by its specific activation, downstream of Raf, estra-
diol exclusively turns on the p42/p44 MAPK module with
no detectable activation of JNK or p38 MAPK within the
first 16–24 h (33 and data not shown). Second, in contrast
to serum activation that leads to the time-dependent de-
sensitization of p42/p44 MAPK, 
 
b
 
-estradiol induces a per-
sistent p42/p44 MAPK activity. One can therefore easily
manipulate the temporal activation of p42/p44 MAPK by
adding 
 
b
 
-estradiol or the MEK inhibitor PD 98059. It was
Figure 1. Inhibition of the p42/p44 MAPK activity by PD 98059
suppresses MAPK nuclear translocation. CCL39 DRaf-1:ER cells
were grown for 2 d on glass coverslides and serum-deprived for
24 h. Before fixation and p42/p44 MAPK immunolabeling, cells
were treated as follows: (A) control cells were left unstimulated;
(B) cells were stimulated for 3 h with 10% FCS; (C) cells were
stimulated for 3 h with 10% FCS in the presence of 30 mM MEK
inhibitor PD 98059; (D) cells were incubated 3 h in presence of
30 mM PD 98059; (E) cells were stimulated for 3 h with 1 mM es-
tradiol; (F) cells were stimulated for 3 h with 1 mM estradiol in
the presence of 30 mM PD 98059. For more details see Materials
and Methods. Bar, 10 mm.
Figure 2. p42 MAPK activation by serum is transient, whereas it
is persistent when stimulating DRaf-1:ER by estradiol. DRaf-1:
ER cells were stimulated by 10% FCS (A) or 100 nM estradiol
(B) for different periods of time. p42 MAPK activation was mon-
itored by electrophoretic mobility retardation in immunoblot
studies. In lanes 2–7, CCL39 cells were stimulated for 15 min, 3 h,
6 h, 9 h, and 12 h, respectively. The lower band corresponds to in-
active p42 MAPK, and the upper band corresponds to the phos-
phorylated (active) form of p42 MAPK. 
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therefore of interest to compare the p42/p44 MAPK trans-
location in cells stimulated with either serum or 
 
b
 
-estradiol.
 
Activation of the p42/p44 MAPK Signaling Pathway
Is Sufficient to Promote the Nuclear Translocation of 
p42/p44 MAPK
 
Fig. 3 depicts a typical time course of p42/p44 MAPK sub-
cellular localization after stimulation of resting CCL39-
 
D
 
Raf-1:ER cells by either serum of 
 
b
 
-estradiol. First, as il-
lustrated in Fig. 3, 
 
A
 
 and 
 
E
 
, the observed staining for p42/
p44 MAPK shows that in G0-arrested cells, p42/p44
MAPK immunolabeling was predominantly cytoplasmic,
in accordance with our and other previously published re-
sults (8, 18, 27). Second, as judged by immunofluorescence
microscopy, p42/p44 MAPK immunostaining underwent a
complete redistribution in serum-stimulated cells, becom-
ing almost exclusively nuclear after 3 h stimulation (Fig. 3
 
B
 
). After 6 h of serum stimulation, p42/p44 MAPK immu-
nostaining is uniformly distributed throughout the whole
cell (Fig. 3 
 
C
 
). Finally, after 9 h of serum stimulation, p42/
p44 MAPK immunostaining was again predominantly cy-
toplasmic (Fig. 3 
 
D
 
). Interestingly, a 3-h stimulation of the
 
D
 
Raf-1:ER chimera by 
 
b
 
-estradiol was sufficient to induce
by itself the nuclear localization of p42/p44 MAPK (Fig. 3
 
F
 
). In contrast to serum stimulation, activation of the
 
D
 
Raf-1:ER chimera prolonged the nuclear localization of
p42/p44 MAPK for up to 6 h (Fig. 3 
 
G
 
) and 9 h (Fig. 3 
 
H
 
)
after stimulation by 
 
b
 
-estradiol. Furthermore, p42/p44
MAPK nuclear immunostaining was even detected after
15 h of 
 
D
 
Raf-1:ER stimulation (data not shown). Later im-
munohistochemical observations were rendered more dif-
ficult because cells underwent rounding and detachment
by the prolonged activation of this signaling cascade (35
and data not shown). As seen in response to serum,
MAPK nuclear translocation initiated by activation of the
 
D
 
Raf-1:ER chimera was also abrogated in presence of the
MEK inhibitor (Fig. 1, compare 
 
E
 
 and 
 
F
 
).
The results presented above demonstrate that the sole
activation of the p42/p44 MAPK signaling module is suffi-
cient to promote the nuclear localization of p42/p44
MAPK. In addition, the nuclear localization of p42/p44
MAPK correlates well with the degree of activation of the
p42/p44 MAPK pathway. As long as p42/p44 MAPK activ-
ity remains elevated, such as with long-term 
 
D
 
Raf-1:ER
stimulation, p42/p44 MAPK remains in the nucleus. On
the contrary, if activation of the p42/p44 MAPK pathway
decreases to unstimulated levels, as with long term serum
stimulation, p42/p44 MAPK returns to the cytoplasm. We
have shown previously that serum removal was sufficient to
induce the efflux of p42/p44 MAPK from the nucleus within
1 h (27), a result consistent with the present observation.
 
Neosynthesis of Proteins Is Required for p42/p44 
MAPK Nuclear Retention
 
The results presented above indicated that activation of
p42/p44 MAPK cascade was both required and sufficient
for inducing p42/p44 MAPK nuclear translocation. p42/
p44 MAPK activation results from its dual phosphoryla-
tion by MEK (1, 10, 47). This reversible phosphorylation
could explain the reversible nuclear localization of p42/
Figure 3. Time course of p42/p44 MAPK nuclear translocation
parallels their temporal activation. CCL39-DRaf-1:ER cells were
processed as described in Fig. 1. Cells were stimulated with 10%
FCS for 3 h (B), 6 h (C), and 9 h (D) or with 100 nM b-estradiol
for 3 h (F), 6 h (G), and 9 h (H). A and E represent unstimulated
cells (control) in both sets of experiments. Bar, 10 mm.
Figure 4. Inhibition of pro-
tein synthesis by CHX sup-
presses MAPK nuclear accu-
mulation. Parental CCL39
cells were grown on glass
coverslides 2 d before a 24-h
serum deprivation. Before
fixation and p42/p44 MAPK
immunolabeling, as de-
scribed in Materials and
Methods, (A) control cells
were left unstimulated, (B)
cells were stimulated with
10% FCS for 3 h, (C) cells
were treated with the protein
synthesis inhibitor cyclohex-
imide (30 mg/ml), and 15 min
later were stimulated with
10% FCS for 3 h in continu-
ous presence of CHX. Bar,
10  mm.Lenormand et al. Mechanism of p42/p44 MAPK Nuclear Accumulation 629
p44 MAPK. However, we and others have previously
shown that nonphosphorylatable and inactive mutants of
p42/p44 MAPK can still translocate into the nucleus. Thus,
activation of p42/p44 MAPK must modify either its inter-
actions with partner proteins and/or the cell physiology to
induce nuclear accumulation of p42/p44 MAPK. First, we
evaluated whether the activation of transcription induced
by p42/p44 MAPK activation and the resulting neosynthe-
sized proteins contribute to nuclear retention of MAPK.
As illustrated in Fig. 4 C, inhibition of protein synthesis
with 30 mg/ml cycloheximide (CHX) completely blocks
the nuclear localization of p42/p44 MAPK after a 3-h se-
rum stimulation (Fig. 4, compare B and C). Identical re-
sults were obtained when nuclear translocation of p42/p44
MAPK was induced with activation of the chimera DRaf-
1:ER (data not shown).
We demonstrated that the activation of the MAPK
pathway closely parallels to the nuclear translocation of
p42/p44 MAPK; therefore, it was essential to verify that
CHX did not abrogate p42/p44 MAPK activity, since this
would explain the inhibition of nuclear translocation.
Addition of CHX to serum-stimulated CCL39 cells did
not modify the activity (Fig. 5) nor the levels of p42/p44
MAPK (data not shown). Indeed, CHX treatment did not
affect serum stimulation of p42/p44 MAPK measured at 7
min (compare lanes 4 and 5) or at 60 min (compare lanes 7
and 8). CHX treatment even enhanced activation of p42/
p44 MAPK at 3 h (compare lanes 10 and 11), which is in
accordance to previous observations (7). The prolongation
of MAPK activation by CHX treatment may be a conse-
quence of blocking the inducible expression of specific
MAPK phosphatases of the MKP family: MKP-1 (45),
MKP-2 (20, 34), and MKP-3 (19, 36). Thus, the inhibition
of p42/p44 MAPK nuclear translocation by CHX treat-
ment, observed in Fig. 4, cannot be attributed to inhibition
of the p42/p44 MAPK signaling pathway. Furthermore, we
were able to rule out the possibility that CHX exerted its
action via nonspecific effects since inhibition of protein
synthesis by 100 ng/ml anisomycin and inhibition of tran-
scription by 5 mg/ml actinomycin D also prevented p42/
p44 MAPK nuclear localization after serum or DRaf-1:ER
chimera stimulation (data not shown). In addition, we
ruled out a possible effect of CHX via activation of JNK/
p38 stress-activated protein kinases (SAPK) by showing
that IL1-b or low concentrations of anisomycin (two po-
tent activators of SAPKs) did not change the nuclear accu-
mulation of MAPKs in response to serum. Finally, by ana-
lyzing the localization of the transcription factor SP1,
MEK, or a nuclear form of MEK (NLS:MEK), we ruled out
unspecific effects of CHX on the nuclear import/export of
proteins in general (data not shown). Taken together,
these experiments clearly demonstrate that the transcrip-
tional stimulation driven by p42/p44 MAPK activation and
the resulting protein neosynthesis are absolutely required
for the nuclear accumulation of p42/p44 MAPK observed
after 1–3 h of mitogenic stimulation.
Inhibition of Protein Synthesis Triggers the Exit of
p42/p44 MAPK from the Nucleus
We have shown previously that terminating MAPK stimu-
lation by rapid removal of serum growth factor induced
the efflux of nuclear p42/p44 MAPK to the cytoplasm
within 1 h (27). In light of the experiments described in
Fig. 4, which demonstrate that protein neosynthesis is re-
quired for the nuclear accumulation of p42/p44 MAPK, we
formulate the hypothesis that the nuclear efflux induced
by serum removal is caused by a decrease in the synthesis
of proteins associated with p42/p44 MAPK in the nucleus
(nuclear anchors). Therefore, we predict that inhibition of
Figure 5. p42/p44 MAPK activity is prolonged when protein syn-
thesis is blocked by CHX and unaffected when the proteasome
function is blocked by LLnL. Activity of immunoprecipitated
p42/p44 MAPK was analyzed as described in Materials and
Methods. MAPK activity is expressed as fold stimulations over
basal activity. (A) Lane 1, CCL39 cells were left untreated; lanes
2 and 3, cells were treated with CHX and LLnL, respectively, for
3 h; lanes 4–6, cells were stimulated 7 min with 10% FCS; lanes 7–9,
cells were stimulated for 1 h with 10% FCS; lanes 10–12, cells
were stimulated for 3 h with 10% FCS. CHX (30 mg/ml) was
added 15 min before FCS in lanes 5, 8, and 11 (black bars). LLnL
(30  mM) was added 15 min before FCS in lanes 6, 9, and 12
(hatched bars). (B) (Separate experiment) Lane 1, CCL39 cells
were left untreated; lanes 2 and 3, cells were stimulated for 1 h
with 10% FCS; lanes 4 and 5, cells were stimulated 1 h with 100
ng/ml TPA; lanes 6 and 7, cells were stimulated for 3 h with 10%
FCS; lanes 8 and 9, cells were stimulated for 3 h with 100 ng/ml
TPA; lanes 10 and 11, cells were stimulated for 12 h with 10%
FCS; lanes 12 and 13, cells were stimulated for 12 h with 100 ng/
ml TPA. LLnL (30 mM) was added 15 min before FCS or TPA in
lanes 3, 5, 7, 9, 11, and 13 (hatched bars).The Journal of Cell Biology, Volume 142, 1998 630
protein synthesis should accelerate MAPK efflux from the
nucleus.
Fig. 6, B and C, show the localization of p42/p44 MAPK
after 3 and 5 h of serum stimulation, respectively. In both
cases, MAPKs are clearly accumulated in the nucleus with
perhaps a less intense signal at 5 h (Fig. 6 C) because of a
decline in p42/p44 MAPK activity. However, the inhibi-
tion of protein synthesis with CHX for the last 2 h of se-
rum stimulation markedly accelerated the cytoplasmic re-
turn of p42/p44 MAPK (Fig. 6, compare C and E). This
acceleration of MAPK nuclear efflux was already appar-
ent 1 h after CHX addition (Fig. 6 D).
Similarly, when CCL39-DRaf-1:ER cells were stimu-
lated by b-estradiol, which induced a persistent activation
and nuclear accumulation of p42/p44 MAPK (as shown in
Fig. 3), addition of CHX was sufficient to trigger the efflux
of p42/p44 MAPK from the nucleus (data not shown). As
CHX treatment did not abrogate (and even slightly en-
hanced) p42/p44 MAPK activation, we conclude that con-
tinuous protein synthesis is required to retain p42/p44
MAPK in the nucleus.
Inhibition of the Proteasome-dependent Protein 
Degradation Pathway Promotes Nuclear Accumulation 
of p42/p44 MAPK
The experiments presented above led us to propose that
activation of the p42/p44 MAPK pathway triggers the neo-
synthesis of short-lived proteins that contribute to the nu-
clear accumulation of p42/p44 MAPK. A prediction of this
proposal is that the stabilization of short-lived proteins
should prolong the nuclear accumulation of p42/p44
MAPK.
Many short-lived proteins have been found to be tar-
geted and degraded by the proteasome after their ubiqui-
tinylation (39). Thus, to validate this hypothesis we in-
hibited the activity of the proteasome with LLnL, a
membrane-permeable inhibitor of cysteine proteases that
acts upon calpains and proteasomes (42, 46). The action of
LLnL on p42/p44 MAPK subcellular localization was as-
sessed after long-term serum stimulation.
Fig. 7 recapitulates a typical immunolocalization of p42/
p44 MAPK. Mainly cytoplasmic in G0-arrested cells (Fig.
7 A), MAPKs display a clear nuclear localization after 3 h
of stimulation with 10% FCS (Fig. 7 B) and return almost
completely in the cytoplasm after 12 h when cells are be-
ginning to enter S-phase (Fig. 7 C). In a parallel set of
stimulated cells, addition of the proteasome inhibitor
LLnL (30 mM), for 12 h, markedly prevented nuclear
MAPK efflux (Fig. 7, compare D with C). In addition, if
mitogenic stimulation was ended upon serum removal af-
ter 3 h and the cells were incubated for another 9 h in a se-
rum-free medium containing the LLnL, the nuclear local-
ization of p42/p44 MAPK was maintained (Fig. 7 H). We
have previously shown that p42/p44 MAPK activity in ex-
ponentially growing cells is completely abolished after a 3-h
serum removal (our unpublished results). Our results indi-
cate that p42/p44 MAPK nuclear retention can be observed
while MAPK activation is totally abrogated, provided that
the targeted degradation of proteins is halted. Further-
more, we have previously shown that activation of CCL39
cells by nonmitogenic stimuli was not sufficient to pro-
mote nuclear accumulation of p42/p44 MAPK (27). For
example, TPA, which is not mitogenic for CCL39 cells,
does not induce any redistribution of MAPKs in the nu-
cleus (Fig. 7 F). Surprisingly, blocking protein degradation
by addition of LLnL during TPA stimulation for 12 h, trig-
gered the nuclear accumulation of p42/p44 MAPK (Fig. 7,
compare G and F). Interestingly, the nuclear accumulation
of p42/p44 MAPK observed when cells were exposed to
both TPA and LLnL was delayed as compared with that
obtained with mitogenic stimulation (starting at z6 h, data
not shown). For all the experiments presented here, it is
important to note that LLnL alone is not able to stimulate
p42/p44 MAPK activity nor alter the magnitude and tem-
poral profile of stimulated MAPKs by serum (Fig. 5 A,
lanes 6, 9, and 12 and Fig. 5 B, lanes 3, 7, and 11) or upon
addition of TPA (Fig. 5 B, lanes 5, 9, and 12). Thus, any ac-
tion of LLnL on the subcellular localization of p42/p44
MAPK cannot be attributed to the modification of MAPK
activity. Furthermore, treatment with LLnL alone does
not change the cytoplasmic localization of MAPKs in rest-
ing cells (Fig. 7 E). To verify that LLnL does not alter the
general mechanism of nuclear import/export, treatment
with LLnL for 12 h in presence of serum does not modify
the subcellular localization of MEK or of the transcription
factor SP1 (data not shown).
To further eliminate the possibility of nonspecific ef-
fect(s) of LLnL, treatment with lactacystin (Fig. 8 C) mim-
ics the action of LLnL (Fig. 8 B). LLnL is a reversible and
slow-binding inhibitor that blocks proteasome function
and calpain proteases (46), whereas lactacystin, a com-
pound shown to be a more specific proteasome inhibitor,
alkylates irreversibly threonine 1 of the active b subunit of
the proteasome (11, 13).
Taken together, these results show the specific implica-
tion of newly synthesized proteins in the process of nu-
clear retention of p42/p44 MAPK and demonstrates that
Figure 6. Inhibition of protein synthesis triggers the rapid nu-
clear efflux of p42/p44 MAPK. Parental CCL39 cells were grown
on glass coverslides and p42/p44 MAPK immunolabeling was
performed as described in Fig. 1, except that before fixation (A)
control cells were left untreated; (B) cells were stimulated for 3 h
with 10% FCS; (C) cells were stimulated for 5 h with 10% FCS;
(D) cells were stimulated for 3 h with 10% FCS, and then 30 mg/
ml CHX was added for 1 h; (E) cells were stimulated for 3 h with
10% FCS and then 30 mg/ml CHX was added for 2 h. Bar, 10 mm.Lenormand et al. Mechanism of p42/p44 MAPK Nuclear Accumulation 631
these nuclear anchor(s), which retain MAPKs in the nu-
cleus, are finely regulated by the proteasome system.
Discussion
The MAPK cascade constitutes a functional signaling unit
that links surface receptor–mediated signals to nuclear
events. It is interesting that among the six to eight sequen-
tial components of this cascade, only p42 and p44 MAPKs,
the most downstream elements, possess the unique poten-
tial to shuttle between the cytoplasm and the nucleus. This
nuclear translocation was observed in virtually all cell
types in culture (fibroblasts, smooth muscle cells, mesan-
gial cells, epithelial cells, PC12 cells, neurons), occurring in
response to either potent mitogenic stimuli, differentiating
agents, or depolarizing agents (8, 9, 18, 24, 27, 30, 32, 37).
Although we believe that this regulatory mechanism is
central to set the spatiotemporal activity of MAPKs and
therefore their biological function, the mechanism by
which MAPKs translocate to the nucleus upon stimulation
is largely unknown.
In resting cells, p42/p44 MAPK are retained in the cyto-
plasm, presumably via a cytoplasmic anchoring complex.
This notion is based on three findings: (a) Overexpression
of either p42 or p44 MAPK leads to a spontaneous leak-
age of MAPK to the nucleus in the absence of stimuli (27).
We interpreted this finding as a saturation of the cytoplasmic
anchor. (b) MEK, the upstream activator of p42/p44 MAPK,
is permanently excluded from the nucleus by a leucine-
rich short sequence, which acts as a nuclear export signal
(14, 23). (c) Thorner and colleagues have highlighted the
existence of a specific p42/p44 MAPK docking site at the
extreme NH2 terminus of MEK, a site conserved from yeast
to human (3). Based on these observations, we hypothesized
that MEK might represent a good candidate for being part
of a MAPK cytoplasmic anchoring complex, a notion that
has been largely substantiated by Fukuda et al. (15).
In this report, we have been able to identify the signal
triggering MAPK nuclear translocation and its dissocia-
tion from the putative cytoplasmic anchor, and the process
that regulates MAPK nuclear retention. The signal re-
quired to initiate MAPK nuclear translocation is clearly
the activation of the p42/p44 MAPK module. This was
best demonstrated by the use of the DRaf-1:ER–express-
ing cells. Activation of the module downstream of Raf
alone is sufficient to initiate MAPK nuclear stimulation.
This translocation is rapid since in most experiments, entry
into the nucleus can be observed as early as 10 min after
stimulation (our unpublished results), and more impor-
tantly, this action does not require new protein synthesis.
These findings were best visualized by using antibodies
specifically recognizing the doubly phosphorylated and
Figure 7. Inhibition of the proteasome-prolonged serum-induced
MAPK nuclear translocation. Parental CCL39 cells were grown
on glass coverslides, and p42/p44 MAPK immunolabeling was
performed as described in Fig. 1, except that before fixation (A)
control cells were left untreated; (B) cells were stimulated for 3 h
with 10% FCS; (C) cells were stimulated for 12 h with 10% FCS;
(D) cells were stimulated for 12 h with 10% FCS in presence of
30 mM of the proteasome inhibitor LLnL; (E) serum-deprived
cells were grown for 12 h in the presence of 30 mM of LLnL;
(F) cells were stimulated for 12 h with 100 ng/ml of TPA; (G)
cells were stimulated for 12 h 100 ng/ml of TPA in the presence
of 30 mM of LLnL; (H) cells were stimulated for 3 h with 10%
FCS, washed three times, and incubated for 9 h in serum-free me-
dium in the presence of 30 mM of LLnL. Bar, 10 mm.
Figure 8. Inhibition of the
proteasome by either LLnL
or lactacystin prolonged se-
rum-induced MAPK nuclear
translocation. Parental CCL39
cells were grown on glass
coverslides, and p42/p44
MAPK immunolabeling was
performed as described in
Fig. 1, except that before fix-
ation (A) cells were stimu-
lated 9 h with 10% FCS; (B)
cells were stimulated for 9 h
with 10% FCS in the pres-
ence of 30 mM of LLnL; (C)
cells were stimulated for 9 h
with 10% FCS in the pres-
ence of 10 mM lactacystin.
Bar, 10 mm.The Journal of Cell Biology, Volume 142, 1998 632
thus active form of MAPK. Entry into the nucleus of ac-
tive p42/p44 MAPK is seen as soon as 5 min after serum
stimulation (data not shown). This result confirms and ex-
tends the observations of Fukuda et al. (15), demonstrat-
ing the nuclear localization of Xenopus MAPK when in-
jected in conjunction with constitutively active MEK or
v-Ras. More recently, MAPK was also shown to be consti-
tutively nuclear in Ras-transformed cells (5).
How p42 and p44 MAPKs dissociate from the cytoplas-
mic anchoring complex upon activation and enter the nu-
cleus is not entirely clear. One interesting idea proposed
by Seger’s group (23) is that upon serum stimulation, the
MEK–MAPK complex translocates to the nucleus where,
following dissociation, only MEK is rapidly excluded via
its active nuclear export signal sequence. Alternatively,
the model we favor, also proposed by Fukuda et al. (15), is
a rapid dissociation of MAPK in the cytoplasm after retro-
phosphorylation of the anchoring complex via p42/p44
MAPK. Subsequent to this dissociation, MAPKs could
easily translocate to the nucleus via simple diffusion, as il-
lustrated by Nishida’s group (15), although a cotransport
involving association of MAPKs with their NLS-contain-
ing substrates cannot be excluded. This model is not in
contradiction with a previous observation that we and oth-
ers have made concerning the ability of nonphosphorylat-
able mutants of p42/p44 MAPK to translocate to the nu-
cleus upon mitogenic stimulation (18, 27). Under these
circumstances, the endogenous MAPK activity is still ca-
pable of regulating the dissociation of the inactive kinase
from the cytoplasmic complex. Alternatively, a third
model has been recently presented by Khokhlatchev et al.
(26). The authors propose that phosphorylation of Erk2
(p42 MAPK) promotes its homodimerization and nuclear
translocation. Although interesting, this model based on
microinjection studies in fibroblasts awaits validation in
vivo by an independent approach.
In contrast to the rapid process of MAPK dissociation
from the cytoplasmic anchoring complex and nuclear en-
try, the events leading to p42/p44 MAPK nuclear retention
do require new protein synthesis. This process that devel-
ops slowly with time also depends upon activation of the
p42/p44 MAPK module. Indeed, MAPK nuclear retention
mirrors the temporal activation of p42/p44 MAPK. This is
best demonstrated by comparing serum with estradiol
stimulation. The strong and persistent activation of the
MAPK module attained with estradiol in DRaf-1:ER cells
led to a massive and persistent MAPK nuclear retention.
Under these conditions, an arrest of protein synthesis by
CHX is sufficient to provoke an efflux of nuclear MAPK,
although the MAPK module remains fully active. Another
example of disjunction between MAPK activation and nu-
clear retention was obtained by inhibiting the proteasome.
Under conditions where MAPK is transiently stimulated
(TPA, serum during short pulses), MAPK does not accu-
mulate in the nucleus. However, if protein degradation of
short-lived proteins is inhibited by proteasome inhibitors,
then MAPK nuclear retention is observed. This process is
slower than with a physiological stimulation with serum,
but the amplitude of nuclear retention is comparable (see
Figs. 7 and 8). Interestingly, under these conditions of pro-
teasome inhibition, MAPK activity is barely detectable,
and yet MAPK nuclear retention is maximal (see Fig. 5).
Therefore, when protein degradation is inhibited, it seems
that MAPK nuclear retention occurs independently of
MAPK-dependent phosphorylating events. Interestingly,
the only reported case where p42/p44 MAPK nuclear
translocation can occur regardless of its activation was in
REF52 cells treated with thiol-modifying agents such as
phenylarsine oxide and N-ethylmaleimide (31). Consider-
ing that N-ethylmaleimide is known to inhibit one pepti-
dase activity of the proteasome by acting on a critical cys-
teinyl residue (11, 22), this agent could trigger, in some
cells, the nuclear accumulation of p42/p44 MAPK by
blocking the degradation of MAPK nuclear anchors.
We interpret our data by proposing that activation of
the p42/p44 MAPK module leads to the neosynthesis of a
MAPK nuclear anchor protein(s). This MAPK nuclear an-
chor protein(s) is rapidly synthesized upon activation of
the p42/p44 MAPK module and has a very short half-life
(estimated z1 hour). What may be the nature of this nu-
clear anchor protein(s)? It has the characteristic of an
immediate early gene product, and it could well represent
a set of transcription factors, substrates of p42/p44 MAPK,
that have the capacity to accumulate in the nucleus and to
physically interact with their signaling kinases. On the
other hand, the MAPK-specific phosphatases, MKP-1 and
MKP-2, represent another set of nuclear proteins, which
are newly synthesized under the control of p42/p44 MAPK
activity (7) and which share the features of a MAPK an-
choring system. Alternatively, and perhaps more appeal-
ing, the MAPK nuclear anchor might represent a specific
component of the MAPK cascade that, in view of long-
term signaling, has evolved to address a pool of active
MAP kinase in the nucleus. In fact, signals that trigger the
nuclear accumulation of p42/p44 MAPK may not be mito-
genic ones, but in all cases they convey long-term activa-
tion of p42/p44 MAPK. This is the case for differentiation
of PC12 cell (9, 37) and for long-term facilitation of presyn-
aptic cells in Aplysia (30). Alternatively, the pool of MAPKs
in the nucleus could progressively become inactivated by
the emergence of the nuclear MKPs. If this is the case,
then MAPK nuclear retention could be an efficient mecha-
nism of signal desensitization, by sequestering MAPK out of
the cytoplasmic-activating complex. Indeed, nonphosphor-
ylatable and inactive mutated forms of MAPK can accu-
mulate into the nucleus (18, 27), providing an indication
that inactive MAPK can bind to the nuclear anchor(s).
One of the next steps in our future investigation of
MAPK nuclear signaling will clearly be the identification
of the nuclear anchoring components and the analysis of
the MAPK activity from the nuclear pool. Here we have
established a set of conditions that should help to evaluate
among positive “MAPK interactors” obtained from purifi-
cation or by two hybrid screens, those specific components
that contribute to MAPK nuclear retention.
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